Exicure, Inc. (2H0)
XFRA 
NASDAQ (CM) Primary XFRA Summary
2H0 Chart
Why Is Exicure (XCUR) Stock Down 27% Today?
Exicure (NASDAQ: XCUR ) stock is dropping on Monday after the prior early-stage pharmaceutical company's shares underwent a rally on Friday. That rally resulted in shares of XCUR stock rising 76% higher during normal trading hours.
Exicure, Inc. (2H0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Exicure, Inc. ever had a stock split?
Exicure, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Andy Yoo CEO | XFRA Exchange | US30205M3097 ISIN |
| US Country | 7 Employees | - Last Dividend | 28 Aug 2024 Last Split | 22 May 2018 IPO Date |
Overview
Exicure, Inc. is a pioneering biotechnology firm that specializes in creating innovative therapies for neurological disorders and hair loss, leveraging its unique spherical nucleic acid (SNA) technology. Founded in 2011 and based in Chicago, Illinois, Exicure has positioned itself as a leader in the development of groundbreaking SNA-based treatments. The company's focus on advancing its lead program candidate, SCN9A, for neuropathic and chronic pain into preclinical studies underlines its commitment to addressing unmet medical needs. Additionally, Exicure has established significant partnerships with major pharmaceutical companies, such as AbbVie Inc. and Ipsen S.A., to expand its research and development capabilities into new therapeutic areas, including hair loss disorders, Huntington's disease, and Angelman syndrome. These collaborations not only bolster Exicure's research efforts but also pave the way for the commercialization of its innovative therapies.
Products and Services
- SCN9A for Neuropathic and Chronic Pain
This leading program candidate by Exicure is in the stage of preclinical studies, focusing on leveraging SNA technology to combat neuropathic and chronic pain. SCN9A represents a novel approach to pain management, potentially offering a new hope for patients suffering from these debilitating conditions.
- SNA-based Treatments for Hair Loss Disorders
In collaboration with AbbVie Inc., Exicure is developing innovative SNA-based treatments aimed at addressing various forms of hair loss. This effort signifies the company's expansion into dermatological conditions, utilizing its proprietary technology to explore potential solutions for a common yet challenging disorder to treat effectively.
- Spherical Nucleic Acids for Huntington's Disease and Angelman Syndrome
Partnering with Ipsen S.A., Exicure is involved in the research, development, and potential commercialization of spherical nucleic acids designed to target the genetic underpinnings of Huntington's disease and Angelman syndrome. This collaboration highlights Exicure's commitment to broadening the therapeutic applications of its SNA technology to benefit patients with these rare neurological disorders.
Contact Information
